Cargando…
Low frequency of HER2 amplification and overexpression in early onset gastric cancer
BACKGROUND: The recent ToGA trial results indicated that trastuzumab is a new, effective, and well-tolerated treatment for HER2-positive gastric cancer (GC). Although GC mainly affects older patients, fewer than 10% of GC patients are considered early-onset (EOGC) (presenting at the age of 45 years...
| Autores principales: | , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Springer Netherlands
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3063579/ https://www.ncbi.nlm.nih.gov/pubmed/21394646 http://dx.doi.org/10.1007/s13402-011-0021-0 |